603087 logo

Gan & Lee Pharmaceuticals. Stock Price

SHSE:603087 Community·CN¥37.4b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

603087 Share Price Performance

CN¥0
-46.87 (-100.00%)
CN¥0
-46.87 (-100.00%)
Price CN¥0

603087 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with high growth potential.

1 Risk
3 Rewards

Gan & Lee Pharmaceuticals. Key Details

CN¥3.8b

Revenue

CN¥949.7m

Cost of Revenue

CN¥2.9b

Gross Profit

CN¥2.0b

Other Expenses

CN¥925.7m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Apr 23, 2026
1.56
75.32%
24.06%
0%
View Full Analysis

About 603087

Founded
1998
Employees
5245
CEO
Kai Du
WebsiteView website
www.ganlee.com

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and other medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People’s Republic of China.

Recent 603087 News & Updates

Recent updates

No updates